MDACC Study No:2009-0801 ( NCT No: NCT01060904)
Title:A phase 1 dose-escalation safety study of brentuximab vedotin in
combination with multi-agent chemotherapy as frontline therapy
in patients with Hodgkin lymphoma
Principal Investigator:Michelle A. Fanale
Treatment Agent:Adriamycin; Bleomycin; Dacarbazine; SGN-35; Vincristine
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of brentuximab vedotin when given in combination with the chemotherapy
combination Adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine
(known as ABVD) and when given combination with the chemotherapy combination
Adriamycin (doxorubicin), vinblastine, and dacarbazine (known as AVD) to
patients with Hodgkin lymphoma. The safety of this drug combination will also
be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:Adriamycin
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Seattle Genetics, Inc.
Return Visit:Screening, cycle 1 day 1 and 15, Cycle 2 day 1, 15 and 28, Cycle 3-6 Day 1 and
Day 15, EOT
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults